跳到正文
MMadical AI Use
示意性醫院

A navigator list for people overdue for cancer screening

此語言的正文尚未翻譯,暫以英文顯示。

示意性情境。這是供規劃用的組合示例,不是某項同行評議試驗的報告。

This is an illustrative composite, not a trial report. A registry ranks patients who are overdue for a fit test, mammogram, or other screening the health system already recommends. Navigators call down the list. Before anyone trusts the rank order, the team checks whether the score under-calls a language group, a neighborhood, or a payer. No detection-rate improvement is claimed. A biased rank can widen a gap the program meant to close.

臨床場景

A health-system population health team with navigators, working from an existing screening registry rather than from a new disease label.

工具與廠商

  • Population health registry
  • Outreach workqueue

來源

Illustrative composite, Madical AI Use · 2026年3月18日 · 年份 2026

收入索引 2026年3月18日

打開來源

標籤

  • 人群
  • 公平性
  • 篩查

供教育和市場掃描的目錄條目。不是醫療建議,也不是背書。

公共衛生與人群

公共項目

A wastewater trend brief for the public health desk

The U.S. CDC National Wastewater Surveillance System publishes pathogen trends from sewage, which health departments read next to emergency and lab data. Some jurisdictions add a statistical nowcast on top of that feed. This card is about the desk workflow, not a claim that a named model forecasts incidence with a stated error. Wastewater is a population signal. It does not diagnose a person.

CDC NWSS · Local epidemiology desk

新聞 · 2024閱讀案例

影像與放射

監管授權

Autonomous diabetic retinopathy screening in primary care

IDx-DR, now marketed as LumineticsCore by Digital Diagnostics, was authorized to screen adults with diabetes for more-than-mild diabetic retinopathy without an eye specialist reading the photo first. A primary care team captures images on a specified retinal camera and the software returns a refer-or-rescreen result. It is not a complete eye examination. Pregnancy and several existing retinal conditions sit outside the labeled use.

LumineticsCore (IDx-DR) · Digital Diagnostics · Topcon NW400

新聞 · 2018閱讀案例

影像與放射

已發表

AI-supported reading in the MASAI mammography trial

The MASAI trial in Sweden randomly assigned screening mammograms to AI-supported reading or standard double reading without AI. Transpara scored each exam and routed lower scores to a single reader and the highest score to double reading, with detection marks available on higher-risk exams. This card quotes the prespecified interim safety analysis, not a claim that every screening program should switch.

Transpara 1.7.0 · ScreenPoint Medical

論文 · 2023閱讀案例
贊助

向閱讀本目錄的臨床與健康科技讀者展示。

查看贊助